Company: PTHS
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001753926-25-000503
Chunk: 97

Company: Pelthos Therapeutics Inc.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 97
---

    if the future market
    price of our Common Stock declines, purchasers of shares of Common Stock may be unable to resell such shares at or above the
    price at which they acquired them. We cannot assure such purchasers that the market of our Common Stock will not fluctuate
    or decline significantly in the future, in which case investors could incur substantial losses.

Further,
we may incur rapid and substantial increases or decreases in our Common Stock price in the foreseeable future that may not coincide
in timing with the disclosure of news or developments by or affecting us. Accordingly, the market price of our Common Stock may
fluctuate dramatically, and may decline rapidly, regardless of any developments in our business. Overall, there are various factors,
many of which are beyond our control, that could negatively affect the market price of our Common Stock or result in fluctuations
in the price or trading volume of our Common Stock, including:

    ●
    actual or anticipated
    variations in our annual or quarterly results of operations, including our earnings estimates and whether we meet market expectations
    with regard to our earnings;

    ●
    our current inability
    to pay dividends or other distributions;

56 

    ●
    publication of research
    reports by analysts or others about us or the industry in which we operate, including the pharmaceutical or biotechnology
    industry which may be unfavorable, inaccurate, inconsistent or not disseminated on a regular basis;

    ●
    changes in market
    valuations of similar companies;

    ●
    market reaction
    to any additional equity, debt or other securities that we may issue in the future, and which may or may not dilute the holdings
    of our existing stockholders;

    ●
    additions or departures
    of key personnel;

    ●
    actions by institutional
    or significant stockholders;

    ●
    short interest in
    our Common Stock or our other securities and the market response to such short interest;

    ●
    the dramatic increase
    in the number of individual holders of our Common Stock and their participation in social media platforms targeted at speculative
    investing;

    ●
    speculation in the
    press or investment community about our company or industries in which we operate;

    ●
    strategic actions
    by us or our competitors, such as acquisitions or other investments;

    ●
    legislative, administrative,
    regulatory or other actions affecting our business, our industry, including positions taken by the FDA;

    ●